Cargando…

Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients

Necroptosis plays a major role in breast cancer (BC) progression and metastasis. Besides, necroptosis also regulates inflammatory response and tumor microenvironment. Here, we aim to explore the predictive signature based on necroptosis-related genes (NRGs) for predicting the prognosis and response...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Honghao, Lv, Wenchang, Tan, Yufang, He, Xiao, Wu, Yiping, Wu, Min, Zhang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306193/
https://www.ncbi.nlm.nih.gov/pubmed/35864548
http://dx.doi.org/10.1186/s12967-022-03535-z
_version_ 1784752493340655616
author Yu, Honghao
Lv, Wenchang
Tan, Yufang
He, Xiao
Wu, Yiping
Wu, Min
Zhang, Qi
author_facet Yu, Honghao
Lv, Wenchang
Tan, Yufang
He, Xiao
Wu, Yiping
Wu, Min
Zhang, Qi
author_sort Yu, Honghao
collection PubMed
description Necroptosis plays a major role in breast cancer (BC) progression and metastasis. Besides, necroptosis also regulates inflammatory response and tumor microenvironment. Here, we aim to explore the predictive signature based on necroptosis-related genes (NRGs) for predicting the prognosis and response to therapies. Using Lasso multivariate cox analysis, we firstly established the NRG signature based on TCGA database. A total of 6 NRGs (FASLG, IPMK, FLT3, SLC39A7, HSP90AA1, and LEF1), which were associated with the prognosis of BC patients, were selected to establish our signature. Next, CIBERSORT algorithm was utilized to evaluate immune cell infiltration levels. We compare the response to immunotherapy using IMvigor 210 database, and also compared immune indicators in two risk groups via multiple methods. The biological function of IPMK was explored via in vitro verification. Finally, our results indicated that the signature was an independent prognostic indicator for BC patients with better efficiency than other reported signatures. The immune cell infiltration levels were higher, and the response to immunotherapy and chemotherapy was better in the low-risk groups. Besides, other immunotherapy-related factors, including TMB, TIDE, and expression of immune checkpoints were also increased in the low-risk group. Clinical sample validation showed that CD206 and IPMK in clinical samples were both up-regulated in the high-risk group. In vitro assay showed that IPMK promoted BC cell proliferation and migration, and also enhanced macrophage infiltration and M2 polarization. In summary, we successfully established the NRG signature, which could be used to evaluate BC prognosis and identify patients who will benefit from immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03535-z.
format Online
Article
Text
id pubmed-9306193
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93061932022-07-23 Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients Yu, Honghao Lv, Wenchang Tan, Yufang He, Xiao Wu, Yiping Wu, Min Zhang, Qi J Transl Med Research Necroptosis plays a major role in breast cancer (BC) progression and metastasis. Besides, necroptosis also regulates inflammatory response and tumor microenvironment. Here, we aim to explore the predictive signature based on necroptosis-related genes (NRGs) for predicting the prognosis and response to therapies. Using Lasso multivariate cox analysis, we firstly established the NRG signature based on TCGA database. A total of 6 NRGs (FASLG, IPMK, FLT3, SLC39A7, HSP90AA1, and LEF1), which were associated with the prognosis of BC patients, were selected to establish our signature. Next, CIBERSORT algorithm was utilized to evaluate immune cell infiltration levels. We compare the response to immunotherapy using IMvigor 210 database, and also compared immune indicators in two risk groups via multiple methods. The biological function of IPMK was explored via in vitro verification. Finally, our results indicated that the signature was an independent prognostic indicator for BC patients with better efficiency than other reported signatures. The immune cell infiltration levels were higher, and the response to immunotherapy and chemotherapy was better in the low-risk groups. Besides, other immunotherapy-related factors, including TMB, TIDE, and expression of immune checkpoints were also increased in the low-risk group. Clinical sample validation showed that CD206 and IPMK in clinical samples were both up-regulated in the high-risk group. In vitro assay showed that IPMK promoted BC cell proliferation and migration, and also enhanced macrophage infiltration and M2 polarization. In summary, we successfully established the NRG signature, which could be used to evaluate BC prognosis and identify patients who will benefit from immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03535-z. BioMed Central 2022-07-21 /pmc/articles/PMC9306193/ /pubmed/35864548 http://dx.doi.org/10.1186/s12967-022-03535-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yu, Honghao
Lv, Wenchang
Tan, Yufang
He, Xiao
Wu, Yiping
Wu, Min
Zhang, Qi
Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
title Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
title_full Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
title_fullStr Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
title_full_unstemmed Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
title_short Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
title_sort immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306193/
https://www.ncbi.nlm.nih.gov/pubmed/35864548
http://dx.doi.org/10.1186/s12967-022-03535-z
work_keys_str_mv AT yuhonghao immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients
AT lvwenchang immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients
AT tanyufang immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients
AT hexiao immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients
AT wuyiping immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients
AT wumin immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients
AT zhangqi immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients